Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Kyverna Therapeutics Inc.

    NASDAQ: KYTX · Real-Time Price · USD
    3.28
    -0.19 (-5.48%)
    At close: Jun 27, 2025, 3:59 PM
    3.28
    0.00%
    After-hours: Jun 27, 2025, 05:50 PM EDT

    Kyverna Therapeutics Statistics

    Share Statistics

    Kyverna Therapeutics has 43.22M shares outstanding. The number of shares has increased by 0.23% in one year.

    Shares Outstanding

    n/a
    		 43.22M

    Shares Change (YoY)

    n/a
    		 0.23%

    Shares Change (QoQ)

    n/a
    		 0.1%

    Owned by Institutions (%)

    n/a
    		 66.01%

    Shares Floating

    n/a
    		 19.46M

    Failed to Deliver (FTD) Shares

    n/a
    		 13,345

    FTD / Avg. Volume

    n/a
    		 3.93%

    Short Selling Information

    The latest short interest is 2.09M, so 4.84% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.09M

    Short % of Shares Out

    n/a
    		 4.84%

    Short % of Float

    n/a
    		 8.43%

    Short Ratio (days to cover)

    n/a
    		 3.96

    Valuation Ratios

    The PE ratio is -1.12 and the forward PE ratio is -0.98. Kyverna Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -1.12

    Forward PE

    n/a
    		 -0.98

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 1

    PB Ratio

    n/a
    		 0.54

    P/FCF Ratio

    n/a
    		 -1.23

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Kyverna Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 8.61

    Quick Ratio

    n/a
    		 8.61

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.07

    Interest Coverage

    n/a
    		 -1004.25

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,138,187.5

    Employee Count

    n/a
    		 112

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -52.72% in the last 52 weeks. The beta is 2.54, so Kyverna Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.54

    52-Week Price Change

    n/a
    		 -52.72%

    50-Day Moving Average

    n/a
    		 2.54

    200-Day Moving Average

    n/a
    		 3.66

    Relative Strength Index (RSI)

    n/a
    		 62.83

    Average Volume (20 Days)

    n/a
    		 339,640

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -142.6M

    Net Income

    n/a
    		 -127.48M

    EBITDA

    n/a
    		 -142.6M

    EBIT

    n/a
    		 -127.62M

    Earnings Per Share (EPS)

    n/a
    		 -3.33
    Full Income Statement

    Balance Sheet

    The company has 96.62M in cash and 8.24M in debt, giving a net cash position of 88.38M.

    Cash & Cash Equivalents

    n/a
    		 96.62M

    Total Debt

    n/a
    		 8.24M

    Net Cash

    n/a
    		 88.38M

    Retained Earnings

    n/a
    		 -263.52M

    Total Assets

    n/a
    		 260.65M

    Working Capital

    n/a
    		 214.36M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -114.25M and capital expenditures -2.21M, giving a free cash flow of -116.45M.

    Operating Cash Flow

    n/a
    		 -114.25M

    Capital Expenditures

    n/a
    		 -2.21M

    Free Cash Flow

    n/a
    		 -116.45M

    FCF Per Share

    n/a
    		 -3.04
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    KYTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for KYTX is $20, which is 474.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $20

    Price Target Difference

    n/a
    		 474.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.69

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist